Thursday, August 13

Browsing: Izabren

Survivors

Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC

By NewsCancerAugust 12, 20260

Izalontamab brengitecan (iza-bren; BL-B01D1), a first-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC), demonstrated encouraging antitumor activity in patients with previously treated…

Treatments

Iza-bren Yields Statistically Significant Efficacy in Advanced TNBC

By NewsCancerFebruary 26, 20260

Statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) were noted with izalontamab brengitecan (iza-bren)…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

Browsing: Izabren

Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC

Iza-bren Yields Statistically Significant Efficacy in Advanced TNBC

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

ARNT Expression Patterns Hold Promise for HIF-1β Inhibition in RCC Subtypes

Latest Post

The dark side of DNA repair: when genome maintenance runs out of fuel

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression

Subscribe to Updates

What's Hot

Browsing: Izabren